EGFR and non-small cell lung carcinoma: Considering the significance of GPS in guiding subsequent treatment, this study focused on exploring tissue and plasma GPS in Chinese patients with advanced NSCLC harboring EGFR Ex19del/L858R mutation at the first-line treatment failure of osimertinib (NCT05219162).